Blood Cancer United Inc
Blood Cancer United Inc. maintains substantial assets despite recent operational deficits and reports no officer compensation.
EIN: 135644916 · Rye Brook, NY · NTEE: G300 · Updated: 2026-03-28
About Blood Cancer United Inc
Blood Cancer United Inc (EIN: 135644916) is a nonprofit organization based in Rye Brook, NY, classified under NTEE code G300. The organization reported total revenue of $569.3M and total assets of $602.0M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Blood Cancer United Inc's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
AI Transparency Report
Mission Effectiveness Score
NonprofitSpending's AI analysis rates Blood Cancer United Inc with a Mission Score of 90 out of 100 (Excellent). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Spending Breakdown
- admin: 10%
- programs: 85%
- fundraising: 5%
According to IRS 990 filings, Blood Cancer United Inc allocates its expenses as follows: admin: 10%, programs: 85%, fundraising: 5%. With 85% directed toward programs, this reflects a strong commitment to its charitable mission.
Executive Compensation Analysis
The organization consistently reports 0% officer compensation across all available filings, indicating that no salaries are paid to officers, which is highly unusual for an organization of this size and suggests a strong commitment to minimizing administrative overhead at the executive level.
Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.
Red Flags
The following concerns were identified during AI analysis of Blood Cancer United Inc's IRS 990 filings:
- Operational deficits in recent years (e.g., 2023 and 2022 where expenses exceeded revenue)
Strengths
The following positive indicators were identified for Blood Cancer United Inc:
- Consistently reports 0% officer compensation, indicating high efficiency in executive overhead.
- Maintains substantial assets, exceeding $600 million, providing a strong financial buffer.
- Significant revenue generation, consistently in the hundreds of millions, demonstrating strong fundraising capacity.
- Long history of IRS 990 filings (13 filings), indicating consistent compliance and transparency.
Frequently Asked Questions about Blood Cancer United Inc
Is Blood Cancer United Inc. financially stable?
While Blood Cancer United Inc. has experienced periods where expenses exceeded revenue (e.g., 2023 and 2022), its substantial asset base, exceeding $600 million, suggests a strong financial foundation capable of absorbing these operational deficits. The overall trend shows significant revenue generation, indicating general stability.
How does Blood Cancer United Inc. manage executive compensation?
Blood Cancer United Inc. reports 0% officer compensation across all 13 available IRS 990 filings. This indicates that no salaries are paid to officers, which is a highly transparent and efficient approach to executive compensation for an organization of its scale.
What is the trend in Blood Cancer United Inc.'s revenue and expenses?
Revenue has fluctuated, with a high of $569,282,300 in the latest period and a low of $271,727,274 in 2016. Expenses have generally followed revenue trends, though in 2023 and 2022, expenses ($386M and $518M respectively) exceeded revenues ($378M and $427M respectively), indicating periods of deficit spending.
Filing History
IRS 990 filing history for Blood Cancer United Inc showing financial trends over 13 years of public records:
Over 13 years of IRS 990 filings (2011–2023), Blood Cancer United Inc's revenue has grown by 33.3%, moving from $283.8M to $378.3M. Total assets increased by 187.1% over the same period, from $224.3M to $643.9M. Total functional expenses rose by 37.5%, from $280.8M to $386.1M. In its most recent filing year (2023), Blood Cancer United Inc reported a deficit of $7.7M, with expenses exceeding revenue. The organization holds $271.3M in liabilities against $643.9M in assets (debt-to-asset ratio: 42.1%), resulting in net assets of $372.6M.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. | |
|---|---|---|---|---|---|---|
| 2023 | $378.3M | $386.1M | $643.9M | $271.3M | — | View 990 |
| 2022 | $427.0M | $518.6M | $693.7M | $321.7M | — | View 990 |
| 2021 | $477.7M | $359.8M | $743.6M | $229.8M | — | View 990 |
| 2020 | $496.2M | $394.0M | $581.7M | $215.6M | — | View 990 |
| 2019 | $396.2M | $367.3M | $454.1M | $185.7M | — | View 990 |
| 2018 | $438.9M | $356.5M | $382.3M | $146.1M | — | View 990 |
| 2017 | $345.3M | $315.5M | $272.3M | $120.0M | — | View 990 |
| 2016 | $271.7M | $254.8M | $217.2M | $99.1M | — | View 990 |
| 2015 | $281.6M | $277.4M | $214.5M | $117.0M | — | View 990 |
| 2014 | $310.1M | $317.2M | $242.6M | $145.4M | — | View 990 |
| 2013 | $290.4M | $307.0M | $236.3M | $135.3M | — | View 990 |
| 2012 | $292.8M | $292.4M | $223.4M | $109.4M | — | View 990 |
| 2011 | $283.8M | $280.8M | $224.3M | $104.5M | — | View 990 |
Year-by-Year Financial Summary
- 2023: Revenue of $378.3M, expenses of $386.1M, and assets of $643.9M (revenue -11.4% year-over-year).
- 2022: Revenue of $427.0M, expenses of $518.6M, and assets of $693.7M (revenue -10.6% year-over-year).
- 2021: Revenue of $477.7M, expenses of $359.8M, and assets of $743.6M (revenue -3.7% year-over-year).
- 2020: Revenue of $496.2M, expenses of $394.0M, and assets of $581.7M (revenue +25.2% year-over-year).
- 2019: Revenue of $396.2M, expenses of $367.3M, and assets of $454.1M (revenue -9.7% year-over-year).
- 2018: Revenue of $438.9M, expenses of $356.5M, and assets of $382.3M (revenue +27.1% year-over-year).
- 2017: Revenue of $345.3M, expenses of $315.5M, and assets of $272.3M (revenue +27.1% year-over-year).
- 2016: Revenue of $271.7M, expenses of $254.8M, and assets of $217.2M (revenue -3.5% year-over-year).
- 2015: Revenue of $281.6M, expenses of $277.4M, and assets of $214.5M (revenue -9.2% year-over-year).
- 2014: Revenue of $310.1M, expenses of $317.2M, and assets of $242.6M (revenue +6.8% year-over-year).
- 2013: Revenue of $290.4M, expenses of $307.0M, and assets of $236.3M (revenue -0.8% year-over-year).
- 2012: Revenue of $292.8M, expenses of $292.4M, and assets of $223.4M (revenue +3.2% year-over-year).
- 2011: Revenue of $283.8M, expenses of $280.8M, and assets of $224.3M.
Data Sources and Methodology
This transparency report for Blood Cancer United Inc is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.